skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy

Journal Article · · Scientific Reports
DOI:https://doi.org/10.1038/srep13028· OSTI ID:1259895
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
FOREIGN
OSTI ID:
1259895
Journal Information:
Scientific Reports, Vol. 5, Issue 2015; ISSN 2045-2322
Publisher:
Nature Publishing Group
Country of Publication:
United States
Language:
ENGLISH

References (57)

Atomic structure of the ectodomain from HIV-1 gp41 journal May 1997
Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant during Therapy with the T20 Fusion Inhibitor journal October 2004
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. journal October 1994
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia journal May 2003
ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer journal May 2014
A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains journal January 2012
Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120 journal January 2005
Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates journal January 2004
A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein journal December 1998
Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell–cell fusion assay journal October 2012
Design of highly potent HIV fusion inhibitors based on artificial peptide sequences journal January 2012
Probing the paramyxovirus fusion (F) protein-refolding event from pre- to postfusion by oxidative footprinting journal June 2014
Cutaneous injection site reactions to long-term therapy with enfuvirtide journal February 2004
Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity journal February 2008
Atomic structure of a thermostable subdomain of HIV-1 gp41 journal November 1997
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors journal March 2004
Core Structure of gp41 from the HIV Envelope Glycoprotein journal April 1997
Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants journal April 2008
An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides journal June 2013
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry journal November 1998
HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES journal February 2007
Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 journal February 2005
HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain journal December 2012
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus journal July 2007
Coot model-building tools for molecular graphics journal November 2004
Remodeling of gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with Target Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Japan Society for the Promotion of Science, and the Japan Health Science Foundation. journal August 2002
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor journal January 2014
Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion journal October 1999
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides journal February 1998
PHENIX: a comprehensive Python-based system for macromolecular structure solution journal January 2010
HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide journal January 2009
The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance journal June 2014
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997
Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy journal April 2015
HIV Entry and Its Inhibition journal May 1998
HIV-1 inhibition by a peptide journal September 1993
Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis journal January 2006
A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody journal June 1999
PHENIX: a comprehensive Python-based system for macromolecular structure solution. text January 2010
The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors journal August 2012
Pharmacokinetics of Enfuvirtide in Patients Treated in Typical Routine Clinical Settings journal January 2006
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors journal September 2003
The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults journal July 2002
A trimeric structural domain of the HIV-1 transmembrane glycoprotein journal December 1995
Fusion Inhibition — A Major but Costly Step Forward in the Treatment of HIV-1 journal May 2003
Identification of minimal sequence for HIV-1 fusion inhibitors journal October 2008
Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor journal February 2008
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains journal October 2008
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America journal May 2003
Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy journal June 2002
Enfuvirtide, an HIV-1 Fusion Inhibitor journal October 2003
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target journal December 1998
Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors journal April 2008
Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro journal September 2005
ADS-J1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the gp41 Pocket Region and Blocking Fusion-Active gp41 Core Formation journal September 2009
Phaser crystallographic software journal July 2007
A Prospective Clinical and Pathological Examination of Injection Site Reactions with the HIV-1 Fusion Inhibitor Enfuvirtide journal October 2006

Cited By (12)

Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide posted_content November 2018
The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association journal January 2019
Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability journal March 2019
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life journal March 2019
Generation of a long-acting fusion inhibitor against HIV-1 journal January 2018
Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations journal September 2016
Pharmacokinetic stability of macrocyclic peptide triazole HIV‐1 inactivators alone and in liposomes journal February 2019
Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors journal August 2019
IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies journal December 2019
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41 journal August 2019
Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide journal May 2019
Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile journal November 2017

Similar Records

Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy
Journal Article · Wed Aug 19 00:00:00 EDT 2015 · Scientific Reports · OSTI ID:1259895
+16 more
A high throughput Cre–lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry
Journal Article · Tue Mar 15 00:00:00 EDT 2016 · Virology · OSTI ID:1259895
+5 more
Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV
Journal Article · Fri Apr 26 00:00:00 EDT 2019 · Antiviral Research · OSTI ID:1259895
+9 more

Related Subjects